Research
Hormonal
Dual and triple incretin agonists (e.g., tirzepatide, retatrutide) offer superior weight loss and glycemic control compared to single GLP-1 agonists.
Newer medications that target multiple hormones (like tirzepatide and retatrutide) are showing even greater weight loss and blood sugar control than older GLP-1 drugs. While promising, they require careful monitoring for long-term safety. These options may be considered if single-agonist therapies are insufficient.
GoodSupportsHIGH confidence
next-generation multi-agonists are establishing new benchmarks for efficacy: the GLP-1/GIP dual agonist tirzepatide results in substantial, enduring weight loss... whereas the triple GLP-1/GIP/glucagon agonist retatrutide attains exceptional phase-2 weight loss
Why this rating
Supported by phase-2 trial data and FDA approvals mentioned in the text.
Source
GLP-1 Receptor Agonists: Advances in Mechanism, Therapeutic Applications, and Future Perspectives
Megha Pawar et al. · BioMed Target Journal · 2025
DOI 10.59786/bmtj.322
narrative_review
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- GLP-1 receptor agonists (e.g., semaglutide 2.4 mg) produce clinically significant weight loss and reduce major adverse cardiovascular events (MACE) in adults with obesity or overweight, regardless of diabetes status.Strong
- GLP-1 receptor agonists provide renoprotective effects by slowing eGFR decline and reducing albuminuria in patients with type 2 diabetes and chronic kidney disease.Strong
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →